AbbVie Inc.
Prices may be delayed up to 20 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ABBV.MX | BMY | LLY | JNJ | PFE | AZN | |
|---|---|---|---|---|---|---|
| Market cap | 9.35T | 124.34B | 1.13T | 616.94B | 169.42B | 261.50B |
| P/E (TTM) | 83.1 | 13.4 | 42.7 | 38.8 | 39.1 | 25.2 |
| Forward P/E | — | 9.2 | 26.9 | 22.0 | 10.3 | 14.9 |
| Price/book | -85.4 | 5.6 | 33.4 | 7.3 | 2.0 | 5.2 |
| Dividend yield | 2.39% | 4.09% | 0.54% | 2.07% | 5.71% | 1.90% |
| 1-year change | +25.74% | +38.95% | +58.00% | +34.43% | +21.80% | +1.17% |
| Today | −0.68% | −1.31% | −1.01% | −1.29% | −1.28% | −0.12% |
The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 20 min.
Latest news
All ABBV.MX news ›Can This Small Biotech Enter A $4.3 Billion AbbVie Market? Rapport Shoots Higher
Allison Gatlin covers biotechnology, pharmaceuticals and medical technology. She also oversees coverage of top-performing companies for Investor's Business Daily's The New America page. Allison has worked for Investor's Business Daily…
AbbVie's Neuroscience Franchise: What to Expect Ahead of Q3 Results
The Zacks Consensus Estimate for AbbVie’s neuroscience revenues in the third quarter of 2026 is pegged at $3.29 billion. The figure implies year-over-year growth of nearly 16%, with growth expected across most marketed products. Turning to…
Zacks Market Edge Highlights: Palantir Technologies, BP, Palo Alto Networks, Visa and AbbVie
Welcome to Episode #503 of the Zacks Market Edge Podcast. Every week, host and Zacks stock strategist, Tracey Ryniec, is joined by guests to discuss the hottest investing topics in stocks, bonds, and ETFs and how it impacts your life. This…
AbbVie's Skyrizi combination delivers higher remission rates in Phase II Crohn's trial
AllSci is an AI-grounded scientific knowledge platform. It aggregates the global scientific literature, patents, grants and trials, atomizes them into hypotheses, questions, results and claims, links everything to canonical entity…
AbbVie’s Crohn’s Combo Topped Skyrizi Alone in a Phase 2a Trial. Here’s What It Means for a Stock Up 24% in 2026
The Street now sits about where the stock does. The mean target was 14.6% above the price on March 31. On October 16 it stood at $282.61, 7 cents below the October 19 close, even after Morgan Stanley’s raise to $310 on October 7. Part of…
AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio
Details on key presentations at ESMO 2026 are available below and the full abstracts are available through the congress online program. Approved medicines and investigational assets referenced are being evaluated in ongoing clinical trials…
AbbVie’s Dividend Keeps Climbing. Is It Still a Buy for Income Investors?
AbbVie's stock has surged nearly 29% this year, but a rising share price compresses the yield even as the dividend keeps growing. Before adding shares for income, consider what the pending Apogee deal and lingering debt load could mean…
Can AbbVie's (NYSE:ABBV) Immunology Duo Offset the Humira Decline?
Did Stronger Steel Earnings Put Nucor (NYSE:NUE) in Focus? Did Stronger Aluminum Earnings Put Alcoa (NYSE:AA) in Focus? The answer so far has been framed as a success. The newer duo has scaled rapidly, growing fast enough to offset the…
AbbVie Named Official Pharmaceutical Partner of the McLaren Mastercard Formula 1 Team, Launches AbbVie Race to Innovate to Support Immunology Community
Fort Technology: Logia USA Signs Exclusive Distribution Agreement to Expand Fuel Maintenance Solutions for Data Centers Across the U.S. Rapport Therapeutics Announces Positive Topline Results from its Phase 2 Trial of RAP-219 for the…
AbbVie Inc. $ABBV Shares Sold by First Bank & Trust
NYSE ABBV opened at $285.32 on Monday. The stock has a market cap of $504.10 billion, a P/E ratio of 80.60, a price-to-earnings-growth ratio of 1.30 and a beta of 0.24. AbbVie Inc. has a fifty-two week low of $190.75 and a fifty-two week…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
theglobeandmail.com42
-
marketscreener.com25
-
gurufocus.com17
-
fool.com12
-
tradingview.com12
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 120 articles, not a forecast.